The Next Phase Of The Obesity Drug Race
The obesity drug market is rapidly evolving beyond Wegovy and Zepbound, with new pills, triple-agonist drugs, and alternative mechanisms entering clinical pipelines. Lilly's experimental Retatrutide showed unprecedented 28% average body weight loss, the highest ever recorded for a drug. Competition is intensifying across weight loss, tolerability, and dosing convenience dimensions.
Summary
The video report covers the current state and near-future pipeline of obesity medications, filmed at the American Diabetes Association's premier obesity conference. Five years after the FDA approved Novo Nordisk's GLP-1 shot Wegovy, both Novo and Eli Lilly have begun rolling out oral pill versions of their treatments, signaling a new competitive phase in the obesity drug race.
Structure Therapeutics shared Phase 2 data showing its small-molecule GLP-1 pill achieved roughly 16% body weight loss — comparable to Lilly's pill — with the added advantage of being easier to manufacture and take. CEO Ray Stevens expressed confidence that patient-driven competition will sustain market room for new entrants, positioning Structure to capture second place behind Lilly's Orforglipron.
The headline data of the conference came from Lilly's experimental triple-agonist drug Retatrutide, which targets three hormone receptors: GLP-1, GIP, and glucagon. At the highest dose, participants lost an average of 28% of body weight, with nearly half losing more than 30% — a threshold associated with bariatric surgery outcomes. Lilly acknowledged this drug would likely target patients with BMI over 40 rather than serve as a broad-market replacement for Zepbound.
Novo's CEO Mike Doustdar reframed the long-term vision for obesity treatment, arguing that obesity will become as differentiated as mental health treatment — encompassing many distinct conditions with tailored medications within the broader cardiometabolic space. Meanwhile, Zealand Pharma and Roche are pursuing a different angle with Petrelintide, an amylin analog that achieved 11% weight loss but with significantly better tolerability, particularly around vomiting. Zealand's CEO believes its superior side-effect profile could trigger an 'iPhone moment' in the market.
Finally, Pfizer and Amgen are competing on dosing convenience. Amgen is testing monthly and quarterly dosing of its experimental drug Maritide, arguing that less frequent injections could reduce patient dropout by lowering the burden of weekly or daily medication schedules. With dozens of drugs potentially launching by 2029, the obesity treatment landscape is set for significant diversification across efficacy, tolerability, and convenience.
Key Insights
- Lilly's experimental Retatrutide produced an average 28% body weight loss at the highest dose, with nearly half of participants losing more than 30% — a level associated with bariatric surgery — making it the most weight loss ever recorded from a drug to date.
- Novo CEO Mike Doustdar argued that obesity will not remain a single monolithic condition but will become as differentiated as mental health treatment, with distinct medications for distinct conditions under the broader cardiometabolic umbrella.
- Structure Therapeutics CEO Ray Stevens said the company is specifically targeting the second market position behind Lilly's Orforglipron, betting that competition among pills ultimately benefits patients and sustains room for new entrants.
- Zealand Pharma's CEO claimed that Petrelintide's superior tolerability — especially reduced vomiting compared to GLP-1 drugs — could trigger an 'iPhone moment,' causing patients to actively queue for the new modality rather than stay on existing treatments.
- Amgen argued that monthly or quarterly dosing of its experimental drug Maritide could meaningfully reduce patient dropout, framing weekly injections and even daily pills as burdensome reminders of disease that disadvantage competing drugs.
Topics
Transcript
[0:00] It's been five years since the FDA approved Novo Nordisk GLP one shot with Govee for weight loss, and that shot in a similar one from Eli Lilly called Zepbound, have transformed the treatment of obesity, helping people lose a significant amount of weight. The drugs are also used now to treat other conditions like sleep apnea and heart problems. Behind these shots, Lilly and Novo have just started rolling out pills, and there are dozens more drugs behind them, including the most powerful drug we've seen yet, Lilly's Retatrutide. I went to the premier obesity meeting the American [0:30] Diabetes Association's to get a look at what else is inside the pipeline. Novo and Lilly introduced GLP one…
Full transcript available for MurmurCast members
Sign Up to AccessMore from CNBC
Watch AI Dock A Boat
CNBC's Contessa Brewer demonstrates a 36-foot Cray boat equipped with advanced marine technology, including GPS, radar, and newly launched autonomous docking capabilities. The boat's base price is $550,000, with fully equipped models featuring autopilot and autonomous docking reaching $880,000.
What Will TV Look Like In 3 Years?
Industry leaders predict that TV will continue its shift toward streaming and live content over the next three years, with cable subscribers declining further and AI enabling personalized, multilingual viewing experiences. Sports remain a critical driver of viewership as one of the few irreplaceable live experiences, while new aggregator services and platforms like Tubi and Roku Channel are expected to gain significant market share.
To keep growing, Best Buy wants to go smaller
Best Buy is launching small and medium-format stores this summer as part of a strategic pivot following years of declining sales and stock performance post-COVID. New CEO Jason Bonfig will take over from Corie Barry in October and plans to accelerate growth through this revised store strategy while capitalizing on the AI boom.
How Audi hopes to win back consumers
Audi is attempting to regain market competitiveness by launching three new premium SUVs, including the Q9 and SQ9, featuring advanced technologies like smart headlights and OLED lighting. The brand has struggled since 2020, falling behind BMW and Mercedes-Benz in quality rankings and market share, with recent losses attributed to tariffs and the end of federal EV subsidies.
Inside SK Hynix: We Went To Korea To See The World's Biggest AI Memory Buildout
SK Hynix, South Korea's memory chip giant, is undertaking a historic $720 billion expansion to triple HBM (high-bandwidth memory) capacity by 2034, driven by unprecedented AI demand. The company is building massive new facilities in Korea while establishing its first U.S. packaging fab in Indiana, though it faces traditional boom-bust cycle risks and competition from Samsung, Micron, and Chinese manufacturers.